Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Return on equity (%)

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndReturn on equity (%) (Million USD)YoY (%)
Dec 31, 2024198.4-10.65%
Dec 31, 2023222.1+101.46%
Dec 31, 2022110.2-52.37%
Dec 31, 2021231.4+117.66%
Dec 31, 2020106.3-350.72%
Dec 31, 2019-42.4+20.69%
Dec 31, 2018-35.1-149.08%
Dec 31, 201771.6-103.65%
Dec 31, 2016-1,959+2463.44%
Dec 31, 2015-76.4-88.06%
Dec 31, 2014-640.2+10.67%
Dec 31, 2013-578.4+222.72%
Dec 31, 2012-179.2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat